AR-13503 SR is under clinical development by Aerie Pharmaceuticals and currently in Phase I for Diabetic Macular Edema. According to GlobalData, Phase I drugs for Diabetic Macular Edema have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AR-13503 SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AR-13503 SR overview
AR-13503 is under development for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema and diabetic retinopathy (PDR), choroidal neovascularization and glaucoma. It is administered through ophthalmic route. The drug candidate acts by targeting multiple kinases including Rho kinase and protein kinase C (PKC). It is a sustained release formulation.
Aerie Pharmaceuticals overview
Aerie Pharmaceuticals (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. The company’s product comprise rhopressa, a once-daily eye drop that is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US, UK and Ireland. Aerie is headquartered in Durham, North Carolina, the US.
For a complete picture of AR-13503 SR’s drug-specific PTSR and LoA scores, buy the report here.